New Drug Shows Promise in Treating Dravet Syndrome

Children with Dravet syndrome typically develop normally until severe seizures begin around age two, followed by a heartbreaking plateau where they stop reaching new milestones while their peers move ahead.

Now, results published in The New England Journal of Medicine show an investigational drug called zorevunersen may actually change the course of the disease. The treatment targets the genetic root cause rather than just managing symptoms.

In studies following patients for up to three years, children taking zorevunersen on top of their regular seizure medications experienced substantial reductions in seizures. Even more remarkably, they showed improvements in communication, motor skills, socialization, and daily living abilities that continued throughout the treatment period.

"While reducing seizures is still critical, the improvements in cognition, behavior and quality of life seen in these studies suggest we may be changing the course of the disease," said Dr. Helen Cross, corresponding author of the study and Director of University College London Great Ormond Street Institute of Child Health.

Mary Anne Meskis, CEO of the Dravet Syndrome Foundation whose son has lived with the condition for over 25 years, put the potential impact in perspective. "A treatment that could help someone like my son dress himself independently or better communicate with his parents would profoundly change the cadence and quality of our everyday lives," she said.

The treatment has been generally well tolerated across 81 patients who received more than 800 doses. The most common side effect was elevated protein levels in cerebrospinal fluid, though no related clinical problems occurred in most cases.

Why This Inspires

For families who watch their toddlers stop developing after seizures begin, this represents more than symptom management. The possibility of helping children continue learning, communicating, and gaining independence transforms what parents can hope for their kids' futures. No approved disease-modifying treatments currently exist for Dravet syndrome.

The discovery of Dravet syndrome's genetic cause 25 years ago opened the door to targeting the root problem rather than just controlling seizures. This approach could become the blueprint for treating other genetic developmental conditions.

A larger Phase 3 study called EMPEROR is currently underway, with results expected in mid-2027 to confirm these promising findings.